Tyler Buckner, MD
Hematology · Aurora, CONPI 1821218827
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,583 of the $60,877 with a category attached, or 63.4%. It is spread thinly across 13 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2020 at $26,228 and has fallen 74.2% since, to $6,763 in 2024.
Across 72 payments — averaging $845.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- CSL Behring$12K
- Bayer$7K
- Sanofi$7K
- Novo Nordisk$5K
- Genentech USA, Inc.$4K
- plus $13K from 7 others
Across 40 payments — averaging $69,454 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.7M
- CSL Behring$39K
- F. Hoffmann-la Roche AG$20K
- Regeneron$19K
- Biomarin Pharmaceutical Inc.$6K
- Pfizer$1K
What the payments were for
- Consulting fees$38,58363%
- Speaking & faculty fees$16,02026%
- Travel & lodging$4,1447%
- Food & beverage$1,9323%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $12,338 |
| CSL Behring | 11 | $11,960 |
| Bayer | 11 | $7,188 |
| Sanofi | 9 | $7,138 |
| Novo Nordisk | 3 | $5,135 |
| Genentech USA, Inc. | 8 | $4,433 |
| Bioverativ Therapeutics Inc. | 1 | $4,433 |
| Shire North American Group Inc | 15 | $4,423 |
| Biomarin Pharmaceutical Inc. | 2 | $2,242 |
| Spark Therapeutics, Inc. | 1 | $1,070 |
| Genentech, Inc. | 5 | $220 |
| AstraZeneca | 1 | $150 |
| Kedrion Biopharma Inc. | 2 | $147 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 74 | $84,588 |
| EliquisApixaban | 25 | $32,438 |
| Tranexamic Acid | 15 | $1,661 |
| Oxycodone Hcl | 18 | $305 |
Paid to pharmacies, not to this prescriber.
Other hematology in Aurora
- Brandon McMahonAurora$9K
- Kathryn HassellAurora$6K
- Thomas KartikaAurora$360
- Lisa ChuAurora$269
- Sally StablerAurora$140
- Olumide OdeyemiAurora$38
- Chelsea HayesAurora$32
- Yazan MigdadyDenver$13K
- Ann HeddermanDelta$6K
- Audrey SatoDenver$31
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.